StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a report released on Tuesday. The brokerage issued a hold rating on the stock.
TherapeuticsMD Price Performance
TXMD stock opened at $1.59 on Tuesday. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.07. The firm has a 50-day simple moving average of $1.69 and a two-hundred day simple moving average of $1.82.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.
Institutional Investors Weigh In On TherapeuticsMD
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Further Reading
- Five stocks we like better than TherapeuticsMD
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 Monster Growth Stocks to Buy Now
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is the Euro STOXX 50 Index?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.